You have 9 free searches left this month | for more free features.

Lymphoma, Mantle-Cell

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)

Not yet recruiting
  • Lymphoma, Mantle-Cell
  • +7 more
  • (no location specified)
Jun 21, 2022

Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma Trial (BGB-11417)

Not yet recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • (no location specified)
Jul 25, 2022

Mantle Cell Lymphoma Trial in Houston (Acalabrutinib)

Recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 22, 2022

Recurrent Refractory Mantle Cell Lymphoma

Recruiting
  • Mantle Cell Lymphoma
    • Beijing, Beijing, China
      Peking University Third Hospital
    Aug 1, 2022

    Newly Diagnosed Mantle Cell Lymphoma Trial in Zhengzhou (Rituximab)

    Recruiting
    • Newly Diagnosed Mantle Cell Lymphoma
    • Zhengzhou, Henan, China
      Department of Oncology, The First Affiliated Hospital of Zhengzh
    Aug 17, 2022

    Untreated Mantle Cell Lymphoma Trial in Suzhou (zanubrutinib and rituximab, BEAM pretreatment, zanubrutinib maintenance)

    Recruiting
    • Untreated Mantle Cell Lymphoma
    • zanubrutinib and rituximab
    • +2 more
    • Suzhou, Jiangsu, China
      the First Affiliated Hospital of Soochow University
    Aug 16, 2022

    Lymphoma, Lymphoma, Mantle-Cell, Tumors by Histologic Type Trial (IM19 CAR-T cells, Cyclophosphamide, Fludarabine)

    Not yet recruiting
    • Lymphoma
    • +4 more
    • IM19 CAR-T cells
    • +2 more
    • (no location specified)
    Nov 30, 2021

    Mantle Cell Lymphoma Trial in Busan (Ixazomib)

    Recruiting
    • Mantle Cell Lymphoma
    • Busan, Western, Korea, Republic of
      Kosin University Gospel Hospital
    Mar 31, 2022

    Mantle Cell Lymphoma Trial in Baltimore (Venetoclax Oral Tablet [Venclexta])

    Recruiting
    • Mantle Cell Lymphoma
    • Venetoclax Oral Tablet [Venclexta]
    • Baltimore, Maryland
      Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Jun 29, 2022

    Relapsed or Refractory Mantle Cell Lymphoma (MCL) Trial in Duarte (BAFFR-CAR T cells)

    Recruiting
    • Relapsed or Refractory Mantle Cell Lymphoma (MCL)
    • BAFFR-CAR T cells
    • Duarte, California
      City of Hope Medical Center
    Jul 5, 2022

    Mantle Cell Lymphoma Trial (Acalabrutinib, Rituximab)

    Not yet recruiting
    • Mantle Cell Lymphoma
    • (no location specified)
    Aug 4, 2021

    Lymphoma, Mantle Cell, Mantle Cell Lymphoma Trial run by the NCI (Rituximab (R), EPOCH, Bortezomib (B))

    Active, not recruiting
    • Lymphoma, Mantle Cell
    • Mantle Cell Lymphoma
    • Rituximab (R)
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Sep 21, 2021

    Lymphoma, Mantle Cell Lymphoma Trial in Houston (Acalabrutinib, Rituximab, Brexucabtagene Autoleucel)

    Not yet recruiting
    • Lymphoma
    • Mantle Cell Lymphoma
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 10, 2022

    Mantle Cell Lymphoma Trial in United States (lenalidomide, rituximab)

    Active, not recruiting
    • Mantle Cell Lymphoma
    • Tampa, Florida
    • +3 more
    Mar 26, 2022

    Follicular Lymphoma, Mantle Cell Lymphoma Trial in New York (Ribavirin)

    Terminated
    • Follicular Lymphoma
    • Mantle Cell Lymphoma
    • New York, New York
      Weill Cornell Medicine
    Sep 20, 2021

    Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma Trial in Madison (Bendamustine, Obinutuzumab)

    Recruiting
    • Mantle Cell Lymphoma
    • +2 more
    • Madison, Wisconsin
      University of Wisconsin Carbone Cancer Center
    Mar 7, 2022

    Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)

    Recruiting
    • Mantle Cell Lymphoma
    • Refractory Lymphoma
    • Boston, Massachusetts
    • +1 more
    Aug 8, 2022

    Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Eprenetapopt, Venetoclax)

    Withdrawn
    • Recurrent Mantle Cell Lymphoma
    • Refractory Mantle Cell Lymphoma
    • Houston, Texas
      M D Anderson Cancer Center
    Feb 23, 2022

    Mantle Cell Lymphoma Trial in Duarte, Ann Arbor, Columbus (Venetoclax, Lenalidomide, Rituximab)

    Active, not recruiting
    • Mantle Cell Lymphoma
    • Duarte, California
    • +2 more
    May 17, 2022

    Mantle Cell Lymphoma Trial in Tianjin (Orelabrutinib in in combination of rituximab and lenalidomide(OLR))

    Recruiting
    • Mantle Cell Lymphoma
    • Orelabrutinib in in combination of rituximab and lenalidomide(OLR)
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Insititute & Hospital
    Nov 3, 2021

    Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte, New Haven (Copanlisib Hydrochloride,

    Recruiting
    • Recurrent Mantle Cell Lymphoma
    • Refractory Mantle Cell Lymphoma
    • Duarte, California
    • +1 more
    Aug 3, 2022

    Mantle Cell Lymphoma Trial in Beijing (DTRMWXHS-12)

    Active, not recruiting
    • Mantle Cell Lymphoma
    • Beijing, China
      Peking University Cancer Hospital
    Aug 18, 2021

    Mantle Cell Lymphoma Trial in Seoul (RB/RBAC alternating, RB)

    Not yet recruiting
    • Mantle Cell Lymphoma
    • RB/RBAC alternating
    • RB
    • Seoul, Gangnam-Gu, Korea, Republic of
      Samsung Medical Center
    Apr 18, 2022

    Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Biospecimen Collection, Follow-Up)

    Active, not recruiting
    • Recurrent Mantle Cell Lymphoma
    • Refractory Mantle Cell Lymphoma
    • Biospecimen Collection
    • Follow-Up
    • Houston, Texas
      M D Anderson Cancer Center
    May 4, 2022

    Mantle Cell Lymphoma Trial in Saint Louis (Bendamustine, Rituximab, Acalabrutinib)

    Active, not recruiting
    • Mantle Cell Lymphoma
    • Saint Louis, Missouri
      Washington University School of Medicine
    Feb 2, 2022